Wagner B, Eichler H G, Schneider B, Blöchl-Daum B, Brenner B, Gasic S, Lechner K, Kyrle P A
Department of Medicine I, University of Vienna, Austria.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):453-6. doi: 10.1007/BF00171089.
We have studied in 12 healthy volunteers the effects of two angiotensin-converting enzyme (ACE) inhibitors, captopril and cilazapril, on vascular and platelet prostaglandin metabolism, in a double-blind, placebo-controlled, randomized cross-over study. Formation of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and thromboxane B2 (TxB2) was measured locally at the site of a microvascular injury. Similar amounts of TxB2 and 6-keto-PGF1 alpha were generated following administration of either ACE inhibitor as compared to placebo. It is concluded that neither captopril nor cilazapril significantly influence vascular and platelet prostaglandin metabolism.
在一项双盲、安慰剂对照、随机交叉研究中，我们对12名健康志愿者进行了研究，观察两种血管紧张素转换酶（ACE）抑制剂卡托普利和西拉普利对血管和血小板前列腺素代谢的影响。在微血管损伤部位局部测量6-酮-前列腺素F1α（6-酮-PGF1α）和血栓素B2（TxB2）的生成。与安慰剂相比，给予任何一种ACE抑制剂后生成的TxB2和6-酮-PGF1α量相似。结论是卡托普利和西拉普利均未显著影响血管和血小板前列腺素代谢。
